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SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSY1
FIRST BRAZILIAN REGISTRY OF BIOLOGICAL TREATMENT IN 
PSORIASIS PATIENTS: PRELIMINARY CONCEPT AND RESULTS:
Felix PAO1, Azulay-Abulaﬁa L2
1Hospital do Servidor Estadual, Rio de Janeiro, Rio de Janeiro, Brazil, 2Universidade do 
Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES: Monitorize PsO patients under biological therapy to evaluate their 
epidemiologic aspects, therapy safety proﬁle and reveal scientiﬁc knowledge based on 
Registry data. METHODS: GBB initiative was created in Rio de Janeiro involving 
eight sites. Patients are monitored according to GBB Clinical Research Form (CRF) 
that include social-economic aspects, disease history, previous treatment and safety 
and efﬁcacy data. A software has been developed to collect on-line data at the sites. 
RESULTS: One hundred twenty-six (126) patients have already been included in the 
Registry since 2006. The interim analysis has shown that 66% are men and 34% 
women, mainly white (65%). The mean age is 48.5 years old (range of 20 to 80 years 
old). The most frequent disease form was plaque PsO (82%), followed by erythroder-
mic form (23%). Overall, 71% of patients are under Etanercept treatment, 25% Inf-
liximab and 4% Adalimumab. Regarding treatment safety, 4/48 patients of Etanercept 
and 7/28 patients of Inﬂiximab presented adverse events. In general, infectious events 
were rare. Related to time of the disease, 46% of patients presents up to 10 years, 
45% 11 to 30 years and 9% more than 31 years. CONCLUSIONS: Patient registries 
are an essential complement to data obtained from randomized, controlled trials. It 
clariﬁes important questions about the use of therapeutic options in the real life and 
in a long-term perspective. GBB preliminary data has shown the ﬁrst demographic 
and clinical data regarding PsO in our country. In addition is the ﬁrst biological treat-
ment monitorization among those patients. Therefore GBB project is revealing impor-
tant data that will guide Brazilian clinical practice and elucidate important issues in 
PsO scenario. This pivotal initiative will have its data collection intensiﬁed and also 
intends to be disseminated trough other services in Brazil.
PSY2
EFFECT OF WRITTEN EMOTIONAL DISCLOSURE INTERVENTIONS IN 
PERSONS WITH PSORIASIS UNDERGOING NARROW BAND 
ULTRAVIOLET B PHOTOTHERAPY
Paradisi A, Abeni DA, Finore E, Di Pietro C, Sampogna F, Pilla MA, Mazzanti C, Tabolli S
IDI IRCCS, Rome, Italy
OBJECTIVES: A beneﬁcial health effects of emotional writing disclosure (ED) on 
several chronic diseases has been described. The aim of this staudy was to investigate 
the effects of two different ED techniques on disease severity and quality of life (QoL) 
in psoriatic patients treated with UVB therapy. METHODS: Forty patients with pso-
riasis (mean age 45 o 18 years) were randomly assigned to two different ED treatments 
(according to Pennebaker [PW] writing about stressful events, or according to King 
[KW], writing about major life goals), or to a control group (CG). Disease severity 
and QoL were assessed at baseline, halfway through and at the end of UVB treatment, 
and again 4 months after ED. Outcome measures were the PASI and SAPASI scores, 
to assess disease severity; the Skindex-29, to evaluate health-related QoL; and the 
GHQ-12, to assess psychological wellbeing. RESULTS: Statistically signiﬁcant differ-
ences in SAPASI scores were recorded between end of therapy and the ﬁnal assessment 
in KW and CG individuals, whereas no differences were found in PW patients. Dif-
ferences between baseline and ﬁnal Skindex-29 scores were not statistically signiﬁcant 
in any group; nonetheless consistently lower 4-month scores in PW patients indicated 
a better health status. Also, all but the PW patients showed signiﬁcant increases 
between end of UVB therapy and ﬁnal scores on all three scales (emotional, function-
ing and symptoms). Although all groups had similar GHQ scores, KW patients had 
the worst GHQ values, especially at the ﬁnal assessment. CONCLUSIONS: In our 
pilot study, we observed that patients with psoriasis allocated to the writing exercise 
on traumatic and distressing experiences (PW protocol) have a longer period of remis-
sion after phototherapy. This provides preliminary evidence that such a simple and 
inexpensive tool may play a role in enhancing treatment efﬁcacy and QoL, so that 
further research in this area may be warranted.
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
PSY3
MODELO DE COSTO BENEFICIO ENTRE BUPRENORFINA 
TRANSDERMICA, MORFINA PARENTERAL Y OXICODONA ORAL, EN EL 
TRATAMIENTO DE PACIENTES CON DOLOR CRONICO MODERADO A 
SEVERO EN UN SERVICIO DE SALUD DE ATENCION DOMICILIARIA
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OBJECTIVOS: Determinar el beneﬁcio neto comparando la administración transdér-
mica, parenteral y oral de diferentes opioides en un servicio de salud de atención 
domiciliaria en una ciudad de Colombia. METODOLOGÍAS: Basados en la revisión 
bibliográﬁca, considerando datos de equipotencia, forma de administración y asumi-
endo diferencias en el perﬁl de seguridad de cada alternativa, se plantea un análisis 
de costo-beneﬁcio; el beneﬁcio neto medido en ahorros representados por las diferen-
cias en el tratamiento, manejo de reacciones adversas entre las alternativas compara-
das, discriminando los costos atribuibles a estreñimiento y emesis generados por 
cada alternativa. Los datos de costos de administración de cada alternativa se mon-
taron en una matriz que consideró el costo del medicamento e insumos necesarios 
para su administración. Luego del costeo de cada ítem, se realizó un análisis por 
mes de los resultados de la administración de cada tratamiento. RESULTADOS: La 
administración de buprenorﬁna transdérmica presentó un beneﬁcio neto del 50% a 
favor en comparación con Morﬁna parenteral según equivalencia terapéutica. Los 
costos de la Morﬁna se ven aumentados por el manejo adicional de reacciones adversas 
atribuibles a la misma. Al comparar Buprenorﬁna transdérmica con Oxicodona 
oral, se encuentra que el beneﬁcio neto es del 40% a favor de buprenorﬁna. CON-
CLUSIONES: Desde la perspectiva de un proveedor de servicios de salud de atención 
domiciliaria, el uso de Buprenorﬁna transdérmica representa un ahorro en compara-
ción con Morﬁna parenteral y Oxicodona oral, en el tratamiento de pacientes con 
dolor crónico moderado a severo. Los beneﬁcios adicionales de la Buprenorﬁna 
transdérmica se traducen en mayor autonomía del paciente, menor dependencia 
para la administración del tratamiento con optimización de costos para el proveedor 
de salud.
PSY4
ECONOMIC EVALUATION OF METFORMIN, METFORMIN  SIBUTRAMIN 
OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE 
DIABETES PATIENTS
Salinas Escudero G1, Idrovo J2, Zapata L2
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OBJECTIVES: Diabetes mellitus is an important public health problem in Mexico. 
The illness progression is faster when the patient also presents overweight or obesity. 
The objective of this study was to evaluate the clinical and economical impact of the 
use of metformine  sibutramine versus metformine and acarbose as a treatment for 
weight loss in patients with DM-2 with obesity and/or overweight, in Mexico. 
METHODS: Cost-effectiveness analysis by decision tree of the pharmacological treat-
ments for weight loss in patients with diabetes mellitus II from the health service 
 provider perspective, considering a temporary horizon of 5 years. The considered 
effectiveness measure was the percentage of patients that reaches an IMC a 25 without 
peritoneal dialysis. Costs were estimated using 2008 prices and are expressed in US 
dollars (exchange rate of 11.14 pesos/ 1 US dollar). RESULTS: According to the 
model, the effectiveness of each alternative was: metformine, 2.16%; acarbose, 2.16% 
and metformine  sibutramine 50.18%. The treatement with metformine threw the 
lowest average cost per treated patient with DM-2 $9,486.3, followed by the treat-
ments with metformine  sibutramine y acarbose with a cost of $10,729.3 y $10,892.0 
respectively. The average treatment cost-effectiveness in ascending order is: met-
formine  sibutramine $21,383.5, metformine $438,183.3; and acarbose $503,116.7. 
The incremental cost of metformine  sibutramine is $2,589.1 and acarbose is an 
alternative dominated by metformine. CONCLUSIONS: Metformine  sibutramine is 
a costeffective alternative from the institutional perspective, in order to accomplish 
the weight loss in patients with diabetes mellitus type 2, with obesity or overweight 
in Mexico.
PSY5
IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND 
PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
Reich K1, Han C2, Szapary P3, Yeilding N3, Ortonne JP4, Schenkel B2, Langley R5
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OBJECTIVES: We evaluated the impact of depression, anxiety, and psoriasis treat-
ment on employability and productivity in patients with moderate-to-severe psoriasis. 
METHODS: In PHOENIX 2, 1230 patients with moderate-to-severe psoriasis were 
randomized to receive ustekinumab 45mg, 90mg, or placebo at wks0 and 4, then 
q12wks, with placebo crossover to ustekinumab at wk12. Anxiety and depression 
were deﬁned using the HADS (score  7 for each scale) and productivity and work 
limitations were assessed using a VAS and Work Limitations Questionnaire. Unem-
ployable patients were deﬁned as those who were currently unemployed and could 
not work even if a job was available. Spearman correlations, or multiple linear and 
logistic regression models were used to measure associations between employability 
and depression or anxiety adjusting for age, gender, disease duration, and PASI. 
Patients of working age (18–64 years) (N  1154) were included in this analysis. 
RESULTS: At baseline, 40.8% of patients experienced anxiety, 26.8% experienced 
depression, while 8.7% were unemployable due to their psoriasis. Depression was the 
most signiﬁcant variable associated with a higher probability of being unemployable 
(RR  2.7, p  0.001). Depression or anxiety were correlated with lower productivity 
and higher work limitations independent of PASI in the regression models (p-values 
 0.01). Improvement in depression or anxiety scores was signiﬁcantly correlated with 
improvement in work limitations and work productivity, even after adjustment for 
improvement in PASI. Greater improvement in work productivity and work limita-
tions were observed after treatment with ustekinumab vs. placebo at wk12 (p  0.01), 
especially among the subgroup with depression or anxiety at baseline. Among unem-
ployable patients who had depression or anxiety at baseline, 44% in the combined 
ustekinumab group vs. 14.3% in the placebo group became employable at wk12 
(p  0.05). CONCLUSIONS: Depression or anxiety in patients with moderate-to-
severe psoriasis is associated with poor employability and low work productivity. 
Treatment with ustekinumab signiﬁcantly improved both employability and produc-
tivity in this comorbid population.
